COMPARISON OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) TREATED WITH DISEASE MODIFYING TREATMENTS (DMT) IN EUROPE (EU) AND THE UNITED STATES (US)

被引：0
|
作者：
Narayanan, S. [1 ]
O'Meara, P. [2 ]
White, J. [3 ]
Chan, J. [3 ]
Hooper, R. [3 ]
Baynton, E. [3 ]
机构：
[1] Ipsos Healthcare, Washington, DC USA
[2] Ipsos Healthcare, New York, NY USA
[3] Ipsos Healthcare, London, England
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND99
引用
收藏
页码：A766 / A766
页数：1
相关论文
共 50 条
  • [1] CHARACTERISTICS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) TAKING INJECTABLE AND ORAL DISEASE MODIFYING TREATMENTS (DMT) IN EUROPE (EU)
    Narayanan, S.
    O'Meara, P.
    White, J.
    Chan, J.
    Hooper, R.
    Baynton, E.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A766 - A766
  • [2] TREATMENT DYNAMICS AND DISEASE BURDEN AMONG PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS (RRMS) CURRENTLY TREATED WITH DISEASE MODIFYING TREATMENTS (DMTS) IN THE UNITED STATES
    Narayanan, S.
    Khan, H.
    Gabriele, S.
    White, J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A65 - A65
  • [3] Treatment patterns of relapsing remitting multiple sclerosis (RRMS) in Europe and the United States
    White, J. L.
    Gabriele, S.
    Hooper, R.
    Brown, H.
    Shah-Manek, B.
    Dibonaventura, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 668 - 669
  • [4] CHARACTERISTICS OF PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TAKING INJECTABLE AND ORAL DISEASE MODIFYING TREATMENTS IN THE UNITED STATES
    Narayanan, S.
    O'Meara, P.
    White, J.
    Chan, J.
    Gabriele, S.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A404 - A404
  • [5] Consistent effects of daclizumab in disease-modifying therapy (DMT)-naive relapsing-remitting multiple sclerosis (RRMS) patients in DECIDE
    Ziemssen, T.
    Giovannoni, G.
    Wiendl, H.
    Greenberg, S.
    Wang, P.
    Aquino, P.
    Giannattasio, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 657 - 658
  • [6] The influence of family planning on treatment decisions in relapsing-remitting multiple sclerosis (RRMS) in Europe and the United States
    White, J.
    Teoh, S.
    Vindici, J.
    Brown, H.
    Gabriele, S.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 397 - 398
  • [7] ADOPTION OF ORAL DISEASE MODIFYING TREATMENTS TO MANAGE PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS FROM 2011-2013 IN THE UNITED STATES
    Narayanan, S.
    O'Meara, P.
    White, J.
    Chan, J.
    Gabriele, S.
    Hautamaki, E.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A405 - A405
  • [8] Leprosy in two patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Fingolimod
    Balasa, Alfred
    Hutton, George
    [J]. NEUROLOGY, 2019, 92 (15)
  • [9] PHREND©: external validation of model to predict individual efficacy of disease modifying therapies (DMT) in relapsing-remitting multiple sclerosis (RRMS)
    Braune, S.
    van Hovell, P.
    Drewek, A.
    Stuhler, E.
    Arnfin, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 798 - 799
  • [10] PATTERNS OF USE OF DISEASE MODIFYING TREATMENTS AMONG PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS IN EUROPE BETWEEN 2012 AND 2016
    Shah-Manek, B.
    Karki, C.
    Brown, H.
    Hooper, R.
    White, J.
    Gabriele, S.
    [J]. VALUE IN HEALTH, 2018, 21 : S265 - S266
12345